Exelixis Has Renewed Momentum Heading Into 2021

The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.

Cancer cells on scientific background.3d illustration
Exelixis' Cabometyx won approval for first-line RCC combined with BMS' Opdivo last month, raising revenue expectations. • Source: Shutterstock

Exelixis, Inc.'s Cabometyx (cabozantinib) receiving US Food and Drug Administration approval combined with Bristol Myers Squibb Company’s Opdivo (nivolumab) in the first-line renal cell carcinoma (RCC) setting is expected to give the former a substantial revenue boost, five years after the US Food and Drug Administration first approved it for advanced RCC.

"We believe we have significant momentum heading into the launch and anticipate a near doubling of cabo RCC revenues by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.